---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-23-000046"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:04:49.755982+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q2 net loss $12.2M; cash runway extended into 2025; IMM-1-104 Phase 1b enrolling

## Summary
- Net loss of $12.2M ($0.43 per share) vs $11.5M ($0.44 per share) in Q2 2022.
- Cash and equivalents $109.0M at June 30, 2023; expects cash runway into 2025.
- Completed $30M underwritten offering of 2.73M shares at $11.00 in April 2023.
- IMM-1-104 Phase 1a dose escalation completed with no dose-limiting toxicities; Phase 1b enrolling at 240mg or 320mg daily.
- RP2D expected early 2024; IND filing for IMM-6-415 expected Q4 2023.

## SEC filing metadata
- accession: 0001790340-23-000046
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/0001790340-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/imrx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-23-000046
- JSON: https://secwatch.observer/filing/0001790340-23-000046.json
- Plain text: https://secwatch.observer/filing/0001790340-23-000046.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported the second quarter ended June 30, 2023 results: net income $12.2 million, or $0.43 per share, EPS $0.43 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $12.2 million, or $0.43 per share
  - EPS: $0.43 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders was $12.2 million, or $0.43 per share, for the quarter ended June 30, 2023, compared to $11.5 million, or $0.44 per share, for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000179034023000046/0001790340-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.